Compare YJ & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | ICU |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | 203 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 13.8M |
| IPO Year | 2019 | 2021 |
| Metric | YJ | ICU |
|---|---|---|
| Price | $1.91 | $3.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 335.0K | 43.6K |
| Earning Date | 03-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,234,000.00 |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $1.11 | $0.22 |
| 52 Week High | $13.97 | $5.38 |
| Indicator | YJ | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 63.24 |
| Support Level | $1.35 | $3.46 |
| Resistance Level | $2.33 | $3.85 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | -0.08 | 0.07 |
| Stochastic Oscillator | 3.72 | 88.10 |
Yunji Inc is a social e-commerce platform in China using a membership-based model that leverages the power of social interaction. The group offers high-quality products at attractive prices and incentivizes members to promote its platform and share products with their social contacts. It empowers prime emerging brands and manufacturers with a deep understanding of market trends and customer behavior to produce high-quality products to meet the demands of members. The company also developed several private labels in the mass consumption field, which are sold on its own platform as well as offered and sold through external channels. It operates in the PRC, and substantially all the Group's revenue is derived from within the PRC.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.